American College of Clinical Pharmacy
      Search      Cart


ACCP Joins Pharmacy Colleagues Calling on CMS to Clarify Guidance on Payment for Pharmacists’ Clinical Services Under the PREP Act

December 16, 2022

ACCP is pleased to join with a coalition of national and state pharmacy organizations in calling on the Centers for Medicare and Medicaid Services (CMS) to clarify guidance stating that state Medicaid and Children’s Health Insurance Program (CHIP) plans should include pharmacists among the members of the health care team authorized for payment for testing and treatment services authorized by the Public Readiness and Emergency Preparedness (PREP) Act declaration.

Current CMS guidance to state health officials regarding mandatory Medicaid and CHIP coverage of COVID-19 testing services does not specifically indicate whether states should reimburse PREP-Act-authorized providers for clinical services necessary for testing and treatment.

In order to facilitate patient access to vital testing and treatment services, including clinical services necessary to prescribe Paxlovid, the pharmacy profession respectfully requests that CMS clarify its position to states.

Click here to read the letter in full.


This website uses cookies to help ACCP provide you with the best user experience. If you continue to use our services, ACCP will assume that you agree to the use of such cookies. You can find out how to update your settings by referring to ACCP’s Policy on Cookies.